R&D expenses for both periods presented generally include compensation and benefit expenses, consulting fees, production supplies, samples, travel costs, utilities and other miscellaneous administrative costs incurred in our ongoing R&D projects.

filing / Aug 6, 2026 / receipt

During the three and six months ended June 30, 2026, restructuring charges were $ 13.0 million and $ 19.9 million, respectively, as compared to $ 8.2 million and $ 15.0 million for the three and six months ended June 30, 2025, respectively, and were primarily related to facility closure costs and severance costs.

filing / Aug 6, 2026 / receipt

• our failure to achieve expected operating efficiencies or expense reductions associated with cost reduction and restructuring efforts;

filing / Aug 6, 2026 / receipt

Restructuring charges Restructuring charges were $13.0 million and $19.9 million for the three and six months ended June 30, 2026, respectively, as compared to $8.2 million and $15.0 million for the three and six months ended June 30, 2025, respectively.

filing / Aug 6, 2026 / receipt

R&D expenses for both periods presented generally included increased compensation and benefit expenses, consulting fees, production supplies, samples, travel costs, utilities and other miscellaneous administrative costs incurred in our ongoing R&D projects.

filing / May 7, 2026 / receipt

During the three months ended March 31, 2026 and 2025, restructuring charges were $ 6.9 million and $ 6.8 million, respectively, and were primarily related to facility closure costs and severance costs.

filing / May 7, 2026 / receipt

• our failure to achieve expected operating efficiencies or expense reductions associated with cost reduction and restructuring efforts;

filing / May 7, 2026 / receipt

Restructuring charges Restructuring charges were $6.9 million and $6.8 million for the three months ended March 31, 2026 and 2025, respectively, and were primarily related to facility closure costs and severance costs.

filing / May 7, 2026 / receipt